Review
doi: 10.1111/j.1749-6632.2003.tb07285.x.
Myocardial Na,K-ATPase and digoxin therapy in human heart failure
Affiliations
- PMID: 12763921
- DOI: 10.1111/j.1749-6632.2003.tb07285.x
Item in Clipboard
Review
Myocardial Na,K-ATPase and digoxin therapy in human heart failure
Ann N Y Acad Sci.
2003 Apr.
Abstract
The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.
Similar articles
-
The Na, K-ATPase in the failing human heart.Cardiovasc Res. 2003 Mar 15;57(4):913-20. doi: 10.1016/s0008-6363(02)00767-8. Cardiovasc Res. 2003. PMID: 12650869 Review.
-
Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure.Cardiovasc Res. 2002 Sep;55(4):710-3. doi: 10.1016/s0008-6363(02)00466-2. Cardiovasc Res. 2002. PMID: 12176120 Review.
-
Human myocardial Na,K-ATPase concentration in heart failure.Mol Cell Biochem. 1996 Oct-Nov;163-164:277-83. doi: 10.1007/BF00408668. Mol Cell Biochem. 1996. PMID: 8974067 Review.
-
No adaptation to digitalization as evaluated by digitalis receptor (Na,K-ATPase) quantification in explanted hearts from donors without heart disease and from digitalized recipients with end-stage heart failure.Am J Cardiol. 1993 Jan 1;71(1):110-4. doi: 10.1016/0002-9149(93)90720-w. Am J Cardiol. 1993. PMID: 8380532
-
Human myocardial and skeletal muscular Na,K-ATPase in relation to digoxin therapy of heart failure.Dan Med Bull. 1997 Nov;44(5):499-521. Dan Med Bull. 1997. PMID: 9408736 Review. No abstract available.
Cited by
-
Celtic Provenance in Traditional Herbal Medicine of Medieval Wales and Classical Antiquity.Front Pharmacol. 2020 Feb 28;11:105. doi: 10.3389/fphar.2020.00105. eCollection 2020. Front Pharmacol. 2020. PMID: 32184721 Free PMC article. Review.
-
Aggregate index of systemic inflammation as a novel prognostic biomarker in Chinese patients with acute decompensated heart failure: a population-based real-world study.Front Endocrinol (Lausanne). 2025 Aug 13;16:1627821. doi: 10.3389/fendo.2025.1627821. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40881126 Free PMC article.
-
"Cardiac glycosides"-quo vaditis?-past, present, and future?Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9521-9531. doi: 10.1007/s00210-024-03285-3. Epub 2024 Jul 15. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39007928 Free PMC article. Review.
-
Ischemia/reperfusion-induced alterations of enzymatic and signaling functions of the rat cardiac Na+/K+-ATPase: protection by ouabain preconditioning.Physiol Rep. 2016 Oct;4(19):e12991. doi: 10.14814/phy2.12991. Physiol Rep. 2016. PMID: 27702882 Free PMC article.
-
Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway.Biosci Rep. 2021 Oct 29;41(10):BSR20211056. doi: 10.1042/BSR20211056. Biosci Rep. 2021. PMID: 34549269 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
